Table 3.
Plasma levels of tested parameters and CA 125 and SCC-Ag in patients with cervical cancer, dysplasia patients and in control group (median and range)
| M-CSF (pg/mL) | VEGF (pg/mL) | CA 125 (U/mL) | SCC-Ag (ng/mL) | ||
|---|---|---|---|---|---|
| Cervical cancer | Squamous cell carcinoma | 510.55a/b/e 102.15–2513.75 |
140.20a/b/c/e 11.80–577.22 |
17.99a/e 4.40–120.10 |
1.20 a/b/c/e 0.50–14.10 |
| Adenocarcinoma | 442.41a/b 95.23–1696.65 |
158.88a/b/e 56.76–615.50 |
15.50 6.34–77.41 |
1.30a 0.70–7.10 |
|
| Total | 500.55 a/e 95.23–2513.75 |
142.00 a/e 11.80–615.50 |
17.60 a/e 4.40–120.10 |
1.20 a/e 0.50–14.10 |
|
| CIN grade | CIN I | 132.40 11.80–615.50 |
47.40 28.20–407.22 |
132.40 11.80–615.50 |
0.74 0.58–0.87 |
| CIN II | 136.90 28.92–395.60 |
48.94 16.90–467.10 |
136.90 28.92–395.60 |
0.70 0.55–1.00 |
|
| CIN III | 199.00 44.50–598.50 |
111.50 27.12–426.86 |
199.00 44.50–598.50 |
0.85 0.65–1.40 |
|
| Total | 312.34 a 126.20–1830.20 |
62.60 16.90–467.10 |
14.90 2.53–78.30 |
0.80 0.30–5.20 |
|
| Control group | 251.50 d/e 119.63–935.29 |
45.80 d 11.20–194.50 |
11.70 3.50–366.00 |
0.75 0.40–1.60 |
|
CA 125: cancer antigen 125; SCC-Ag: squamous cell carcinoma antigen; M-CSF: macrophage-colony stimulating factor; VEGF: vascular endothelial growth factor
aStatistically significant when compared with controls
bStatistically significant when compared with patients with CIN I
cStatistically significant when compared with patients with CIN II
dStatistically significant when compared with patients with CIN III
eStatistically significant when compared with patients with total CIN group